ASU scientists develop new, rapid pipeline for antimicrobials

December 14, 2017

With hospitals more often reaching for antibiotics of last resort to fight infections and recent Ebola and Zika outbreaks crossing borders like never before, the worldwide scientific community has been challenged with developing new antimicrobials to safeguard the population.

The research arm of the U.S. Department of Defense, the Defense Advanced Research Program Agency, or DARPA, is known for taking on out-sized challenges such as this. And so, they put out a call for researchers to figure out how to make at least 1000 doses to any unknown pathogen - in a week.

An ASU team was one of the few that rose to this challenge.

"As far as we know we were the only team to figure out how to do this for any pathogen - virus or bacterium," said research leader Stephen Albert Johnston, who directs the ASU Biodesign Institute's Center for Innovations in Medicine and is a professor in the School of Life Sciences. "While the system is designed to create antimicrobials in an extreme emergency - which we hope is never needed - the basic elements can be applied to improve conventional approaches to making anti-infectives.

"My research center thrives on taking on projects most think cannot be done. This challenge was too good not to respond."

Synthetic sentinels

Antibodies are large, Y-shaped proteins produced by the human immune system to ward off foreign invaders. Our bodies mount this defense rapidly, especially if they have seen the invader before, producing the needed antibody within days of infection.

But to make them in the lab, antibodies specific for just one invader can take months, and be an expensive proposition.

Johnston wanted to mimic nature's approach while dramatically reducing the antimicrobial discovery and production time.

For the past decade, Johnston's team has been a pioneer in developing lab-made versions that focus on just the business end of antibodies, critical pathogen recognition elements, called synthetic antibodies, or synbodies.

Synbodies are made from two short protein fragments, called peptides, which are joined together to form a small, antibody-like compound still large enough to do its job.

Chipping away

But even the process of making synbodies typically takes several months.

Synbodies are selected on peptide chips containing a premade set of 10,000 peptides placed in neat rows on a microscope glass slide, called a microarray.

To generate a synbody with antibiotic activity, a solution containing bacteria or viruses can be placed on the microarray.

"Our solution to save time was to pre-screen a large number of pathogens on the microarray and find 100 peptides that would be diverse enough so that any pathogen screened would bind to two or more peptides," said Chris Diehnelt, an associate research professor in Johnston's center who oversaw the lab experiments.

They could stockpile large stocks of these 100 peptides in advance so that 1,000 or more doses of a therapeutic could be quickly produced, screening the best candidates that block a given pathogen. These candidates are then produced in large amounts, purified and tested in mice for acute toxicity so that the whole process is completed in a week.

For their proof-of-concept, they screened a total of 21 different viruses and bacteria against their synbody arrays.

"We found that the majority of the peptides recognized one pathogen," said Diehnelt.

In addition, they tested their system against two unknown pathogens that were not used in the study.

"The data showed that this array can potentially identify binding peptides for any given pathogen," said Diehnelt.

A shot in the arm

"With this approach, dozens or even hundreds of synbodies can be produced in a day," said Johnston.

The best candidates are quickly evaluated both for effective killing and toxicity to humans and can be produced on a large scale.

Finally, their system was tested against two societal scourges and major worldwide health concerns: a potentially pandemic flu strain (H1N1 influenza) as a viral test and a bacterium that causes surgery-related infections, S. epidermidis.

"Our data indicate that a new virus or bacterium can be screened against the small peptide library to discover binding peptides that can be converted into neutralizing antiviral and antibacterial synbodies in a rapid manner," said Diehnelt.

The next steps would be to prepare the final product for an IV delivery, and to scale up the system to produce enough product for a population-wide use ----should the next Ebola, Zika or unanticipated outbreak occur.

"One key, unique feature of our synbody technology is that the same platform can produce synbodies with direct antibiotic or antiviral activity, and we can do it at a fraction of the potential cost as current, commercially produced therapeutic antibodies," said Johnston.

This is good news for saving lives before the next inevitable outbreak occurs.

And for Johnston, who has also spun out companies based on other ASU technologies he has developed or co-developed, it could also mean big business in addition to the potential to save lives. The global therapeutic monoclonal antibody market and cancer therapies are in high demand, with an estimated market size close to $100 billion for 2018.
-end-
This work was funded by a grant from the Defense Advanced Research Projects Agency (W911NF-10-0299) to professor Stephen Albert Johnston under the 7-Day Biodefense Program.

Arizona State University

Related Antibodies Articles from Brightsurf:

Scientist develops new way to test for COVID-19 antibodies
New research details how a cell-free test rapidly detects COVID-19 neutralizing antibodies and could aid in vaccine testing and drug discovery efforts.

Mussels connect antibodies to treat cancer
POSTECH research team develops innovative local anticancer immunotherapy technology using mussel protein.

For an effective COVID vaccine, look beyond antibodies to T-cells
Most vaccine developers are aiming solely for a robust antibody response against the SARS-CoV-2 virus, despite evidence that antibodies are not the body's primary protective response to infection by coronaviruses, says Marc Hellerstein of UC Berkeley.

Children can have COVID-19 antibodies and virus in their system simultaneously
With many questions remaining around how children spread COVID-19, Children's National Hospital researchers set out to improve the understanding of how long it takes pediatric patients with the virus to clear it from their systems, and at what point they start to make antibodies that work against the coronavirus.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Seroprevalence of antibodies to SARS-CoV-2 in 10 US sites
This study estimates how common SARS-CoV-2 antibodies are in convenience samples from 10 geographic sites in the United States.

Neutralizing antibodies in the battle against COVID-19
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies.

Three new studies identify neutralizing antibodies against SARS-CoV-2
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.

More effective human antibodies possible with chicken cells
Antibodies for potential use as medicines can be made rapidly in chicken cells grown in laboratories.

Read More: Antibodies News and Antibodies Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.